Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
CrystalsFirst logo — Turning Insights Into Medicines

CrystalsFirst

Turning Insights Into Medicines

Founded 2018 Germany Hamburg, Germany 18 employees Non Equity Assistance Total: $756.60K AI, Biotechnology +2

General Information

Company Name CrystalsFirst
Founded Year 2018
Location Germany Hamburg, Germany
Employees 18
Industries AI, Biotechnology, Health Care +1
Funding Stage Non Equity Assistance
Social

BounceWatch is an independent company data service, not affiliated with CrystalsFirst. To contact CrystalsFirst, visit crystalsfirst.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does CrystalsFirst compare?

A PDF of CrystalsFirst and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting CrystalsFirst soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About CrystalsFirst

CrystalsFirst is a biotechnology startup with the slogan "Turning Insights Into Medicines." Founded in 2018 and headquartered in Germany, the company is focused on revolutionizing small molecule drug discovery through its proprietary MAGNET platform. This technology integrates structural biology, generative AI, and medicinal chemistry to detect molecular magnets, identify novel molecules, and druggable binding pockets for challenging targets. By adopting a "crystal structure first" strategy and utilizing computational modeling, the platform facilitates rapid access to diverse chemical scaffolds, hit expansion, and scaffold hopping. Notably, the recent non-equity assistance investment at 01 August 2022 from VentureOut signifies external validation of CrystalsFirst's innovative approach. The synergistic combination of these elements in the MAGNET Platform accelerates the discovery process, increasing the likelihood of finding innovative and effective therapeutic compounds. Overall, CrystalsFirst stands out as an exciting player in the biotechnology, health care, and pharmaceutical industries, poised to make substantial contributions to the advancement of drug discovery and development.

Business keywords: drug discovery, structural biology, computational modelling, generative AI, medicinal chemistry, crystal structure, target interactions, rational design, hit expansion, scaffold hopping, compound generation, therapeutic compounds, innovative technology, pharmaceutical research

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Non Equity Assistance Undisclosed 1
VentureOut
01 Aug 2022
Non Equity Assistance Undisclosed 1
MassChallenge
MassChallenge
15 May 2019
Seed Round €600.00K 1
Hessen Kapital I
14 Mar 2018
Non Equity Assistance €156.60K 1
EXIST
01 Oct 2016

CrystalsFirst Alternatives & Competitors

CrystalsFirst vs
Ventus Therapeutics
Ventus Therapeutics United States

Pioneering a unique approach to structure-based drug discovery. Located in Waltham, MA and Montreal,...

Grant
55 employees
Biotechnology, Health Care
Compare CrystalsFirst vs Ventus Therapeutics
CrystalsFirst vs
Deargen
Deargen Korea South

AI-First Pharmatech Company. We are exploring sequence-based drug discovery and development.

Series B
11 employees
AI, Biotechnology
CrystalsFirst vs
Pharmacelera
Pharmacelera Spain

Mine enhanced chemical space. Design superior candidates

Seed
28 employees
Biotechnology, Information Technology
Compare CrystalsFirst vs Pharmacelera
Also compare with: CrystalsFirst vs Numerate Numerate

FAQ About CrystalsFirst

Turning Insights Into Medicines
CrystalsFirst was founded in 2018.
CrystalsFirst is headquartered in Hamburg, Germany.
CrystalsFirst operates in AI, Biotechnology, Health Care and Pharmaceutical. Its work centres on drug discovery, structural biology, computational modelling and generative AI.
CrystalsFirst has approximately 18 employees.
CrystalsFirst has completed 4 funding rounds, raising a total of $756.60K. The latest funding stage is Non Equity Assistance.
Top alternatives and competitors to CrystalsFirst include Ventus Therapeutics, Deargen, Pharmacelera, Numerate, Circle Pharma, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
CrystalsFirst and Ventus Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for CrystalsFirst, https://bouncewatch.com/company/crystalsfirst, updated 9 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes